# Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

> **NCT06106802** · PHASE2 · RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 47 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** Lazertinib
- **DRUG:** Tepotinib

## Key facts

- **NCT ID:** NCT06106802
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-11
- **Primary completion:** 2029-09-30
- **Final completion:** 2029-09-30
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06106802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06106802, "Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06106802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*